Falsified Medicines Directive
Impact for Wholesalers

Wholesale Distribution Information Day, 28th September 2012

Lorraine Nolan
Healthcare Products
Distribution Manager
Contents

1. Falsified medicines legislation
2. Main changes & requirements
3. GDP aspects
4. IMB approach to implementation

amending Directive 2001/83 on the Community code for medicinal products for human use, as regards the prevention of entry into the legal supply chain of falsified medicinal products

Published 1st July 2011

Entry into force 2nd January 2013
Main Changes

1. **Active Substance (API)**
2. **Safety Features**
3. **Supply Chain & GDP**
4. **Internet Sales**
Definition: Falsified Medicinal Product

Any medicinal product with a false representation of:

a) its identity, including its packaging and labelling, name, composition in respect of any of its components and strength;

b) its source, including the manufacturer, country of manufacturing, country of origin, MAH or

c) its history, including the records and documents relating to the distribution channels used.
Active Substance Requirements

✓ Mandatory **audits** by finished product manufacturers

✓ Registration requirements for manufacturers, importers & distributors

✓ Provisions for import into EU
  • Third country listed by Commission or
  • **Written confirmation for each lot** by 3rd country authorities
Safety Feature Requirements

- POMs
- Some OTCs
- Based on Risk
- Published List
- Technology & Equipment

“White List” - Safety Features
“Black List” - Others
Safety Feature Requirements

Manufacturer
- QP to Verify Application
- Specific requirements for parallel importers

Wholesaler
- Verify Authenticity
- Identify individual packs
- Verify tamper-evidence device intact

Technology & Processes
- Delegated Act
Safety Feature Requirements

✓ Commission “Concept Paper” on the “Delegated Act on the Detailed Rules for a Unique Identifier for Medicinal Products for Human Use, & its Verification”

✓ Public consultation: Nov 2011 to Apr 2012
  http://ec.europa.eu/health/human-use/falsified_medicines/developments/2012-06_pc_safety-features.htm#

• Characteristics and technical specifications
• Modalities for the verification & identification
• Information repository systems
• Risk procedures for product selection

✓ Impact Assessment & Legislative Proposal to follow
Safety Features Requirements

MEDICINAL PRODUCTS FOR HUMAN USE - RESPONSES TO THE PUBLIC CONSULTATION ON THE CONCEPT PAPER ON THE DETAILED RULES FOR UNIQUE IDENTIFIER FOR MEDICINAL PRODUCT FOR HUMAN USE

DIRECTIVE 2011/62/EU to fight against falsified medicines introduces obligatory 'safety features' to allow, inter alia, verification of the authenticity of medicinal products for human use (unique identifier). The Directive places the Commission under an obligation to adopt delegated acts setting out the details relating to inter alia the unique identifier. The enclosed concept paper (93 KB) has been launched for public consultation until 27 April 2012 with a view to preparing both the impact assessment and the delegated act.
<table>
<thead>
<tr>
<th>Safety Features</th>
<th>Practical Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Safety Feature Verification</td>
<td>• <em>Recording of batch numbers linked to safety feature requirements</em></td>
</tr>
<tr>
<td></td>
<td>• Keep informed on EU Developments</td>
</tr>
<tr>
<td></td>
<td>• IMB information day on safety features proposed for 2013</td>
</tr>
<tr>
<td></td>
<td>• Implementation strategy should be developed as the content of the “Delegated Act” progresses</td>
</tr>
<tr>
<td>2. Record of Batch Numbers</td>
<td></td>
</tr>
<tr>
<td><strong>Note 1 &amp; 2: From 2017</strong></td>
<td>- Processes</td>
</tr>
<tr>
<td></td>
<td>- Technologies/Equipment</td>
</tr>
<tr>
<td></td>
<td>- Budget &amp; cost</td>
</tr>
<tr>
<td></td>
<td>- Implementation</td>
</tr>
<tr>
<td></td>
<td>- Validation</td>
</tr>
<tr>
<td></td>
<td>- Training</td>
</tr>
</tbody>
</table>
Supply Chain Requirements

- All distributors subject to requirements
- Provision for introduction of medicines
- Definition & obligations for brokers
- Obligations for “exporting” wholesalers

Actors within Supply Chain
Supply Chain Requirements

Increased Visibility

- WDA
- Union Database
- Non Compliance
- GDP Certificates
Obligation to ensure the authorisation of supply chain participants

Increased quality system requirements

Mandatory reporting requirements for falsified medicines

Record keeping requirements strengthened
Implementation Strategy

- FMD
- Revised EU GDPs
- Union Database
Increased Obligations

✓ Quality Systems
  • Mandatory
  • Use of QRM Principles

✓ Supplier Qualification
  • Verification of compliance with GDP
  • Carrying out & receiving audits
## Quality System

<table>
<thead>
<tr>
<th>Quality System</th>
<th>Practical Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Quality Systems Legal Requirement</td>
<td>• Define procedure for QRM approach</td>
</tr>
<tr>
<td></td>
<td>• Review QMS, processes &amp; systems</td>
</tr>
<tr>
<td>2. Use of QRM</td>
<td>• Identify key risk areas</td>
</tr>
<tr>
<td>Note 1 &amp; 2: From Jan 2013</td>
<td>• Start by focusing on one area</td>
</tr>
<tr>
<td></td>
<td>• Develop implementation plan to include all identified risk areas</td>
</tr>
</tbody>
</table>
# Wholesaling & GDP Requirements

<table>
<thead>
<tr>
<th>Supplier Qualification</th>
<th>Practical Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Verification of Compliance with GDP</td>
<td>• Review existing suppliers/ GAP Analysis</td>
</tr>
<tr>
<td></td>
<td>• Review associated documentation/agreements</td>
</tr>
<tr>
<td></td>
<td>• Explore methods for assessing GDP compliance</td>
</tr>
<tr>
<td></td>
<td>• Based on risk assessment define criteria for auditing suppliers</td>
</tr>
<tr>
<td></td>
<td>• Introduce alternative assessment approaches for non-audited suppliers</td>
</tr>
<tr>
<td></td>
<td>• Proceduralise approach</td>
</tr>
<tr>
<td></td>
<td>• Document the qualification exercise</td>
</tr>
<tr>
<td>2. Conduct &amp; Receive Audits</td>
<td>Note 1 &amp; 2: From Jan 2013</td>
</tr>
</tbody>
</table>

---
## Broker Qualification

<table>
<thead>
<tr>
<th>Practical Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Identify existing brokers utilised &amp; inform of new requirements</td>
</tr>
</tbody>
</table>

### Note 1 & 2: From Jan 2013

- Define & audit programme to include:
  - Frequency & Content
  - Reporting methodology & Follow up

- Use of contract support

- Proceduralise approach

- Document qualification exercise

- Onus on customers to ensure broker is registered
Internet Sales Requirements

✓ Not legitimate in Ireland for POMs
  • National provisions shall apply including those relating to supply of “general sale” products

✓ FMD Requirements
  • Notifications for Internet pharmacies & other “general sale” product suppliers;
  • Notification to include address, website, products offered;
  • Requirement to display new EU logo and link to authority’s website;
  • Member States to list authorised internet “pharmacies”
IMB Implementation

Timeline: September 2011 – January 2013

Project Groups: Six groups reviewing impacted areas
Cross Departmental representation
Policy & procedure updates

National Legislation: Regular interaction with Department of Health on transposition & amending national legislation
Key Messages

- Significant number of changes for wholesalers under FMD: Focus on transparency; traceability; security; accountability

- Revision of EU GDPs supports FMD implementation & necessary to give full effect

- Implementation timelines from 2013 to 2017

- Development of implementation plan will enable compliance with regulatory obligations
Follow Up

Questions

For further information:
lorraine.nolan@imb.ie